三生国健药业(上海)股份有限公司 (688336) Q2 2026 Earnings Call

Concluded Aug 31, 2026

Aug 31, 2026 0 turns

Period: FY2026 Q2
Runtime: —
Sources: 0 artifacts

Executive readout · one minute

Webcast research workspace

Read the call alongside every captured source. Event details are collected in one workspace.

626 BDCA2 for lupus and 627 TL1A for IBD 16 Pfizer 707 partnership and milestones 11 Commercialization build-out 9 Early R&D platform and preclinical pipeline 9 New product launches (608 Yisaituo, 613, IL-1β gout) 8 Mature product pressure from VAT and insurance cost control 7

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes

“上半年公司实现营业收入8. 7亿元同比增长是34. 8% 规模净利润3. 7亿元同比增长95. 1%”
“所以相信两个品种呢在明年会贡献更多更大的一些增量”
“同时受增值税率调整医保控费等多层因素叠加影响存量产品销售端承压”

Research coverage

0 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Company webcastOpen the original investor-relations page

Read transcripts like this one from Claude, ChatGPT or your own code with the earnings call transcript API →